Tonix Pharmaceuticals (TNXP) Investor presentation summary

Product portfolio and financial position

• Three FDA-approved products: Tonmya (fibromyalgia), Tosymra, and Zembrace (both for migraine).

• Focus areas include CNS, infectious disease, immunology, and rare diseases.

• Fully integrated operations: research, development, manufacturing, and commercial.

• ~$208M cash as of December 31, 2025, with no debt and expected runway into Q1 2027.

• Strategic partnerships with major universities and the U.S. federal government.

Tonmya launch and market opportunity

• Tonmya is the first FDA-approved fibromyalgia treatment in over 15 years, launched November 2025.

• $1.4M in net sales in the first ~6 weeks; over 1,500 prescribers and 2,500 patients initiated treatment by February 2026.

• Focused on 5% of HCPs who write 70% of fibromyalgia prescriptions, using a data-driven, targeted approach.

• Robust patient access programs, copay assistance, and payer engagement strategies in place.

• Patent exclusivity extends to 2034, with potential for further extension.

Unmet need and competitive landscape in fibromyalgia

• Over 10 million U.S. adults affected, with high dissatisfaction among patients and prescribers.

• 85% of first-line treatments fail due to efficacy and tolerability issues; high patient churn and polypharmacy.

• Significant off-label opioid use due to lack of effective approved options.

• Tonmya offers a distinct mechanism, robust efficacy, and is generally well-tolerated.